Abstract: A composition and method for converting alcohol to acetaldehyde and/or acetate and treat alcohol intoxication. The composition can include a therapeutically effective amount of an enzyme and a therapeutically effective amount of a co-factor. The enzymes can be alcohol dehydrogenase (ADH), a derivative of alcohol dehydrogenase, an analog of alcohol dehydrogenase or alcohol dehydrogenase in yeast crude extract. A second enzyme can be aldehyde dehydrogenase (ALDH), a derivative of aldehyde dehydrogenase, an analog of aldehyde dehydrogenase, mitochondrial aldehyde dehydrogenase (ALDH2), a derivative of mitochondrial aldehyde dehydrogenase, an analog of mitochondrial aldehyde dehydrogenase or aldehyde dehydrogenase in yeast crude extract. A co-factor can be utilized in the composition that increases a concentration of Nicotinamide Adenine Dinucleotide (NAD) or Nicotinamide Adenine Dinucleotide Phosphate (NADP).

Abstract: A product and method of using albumin nanoparticles for treating multiple traumas by augmenting the function or effectiveness of stem cells or precursor cells in vivo. An albumin nanoparticle suspension containing submicron albumin spheres is prepared, with the albumin spheres being capable of augmenting a function and effectiveness of stem cells or precursor cells in vivo for treating multiple traumas at the same time. A predetermined amount of the albumin nanoparticle suspension is administered to a patient before or after an onset of multiple traumas. A function of the stem or precursor cells can be augmented or improved by the albumin spheres to stimulate mobilization toward the traumas, to ameliorate an inflammatory response of the subject by decreasing an amount of RANTES endothelial production on cytokines production, and/or to improve a secretion of fractalkine. The albumin spheres can be bound with fibrinogen molecules in vitro or in vivo.

Abstract: The present invention relates to a product and method of using albumin nanoparticles for augmenting the function or effectiveness of stem cells or precursor cells in vivo. An albumin nanoparticle suspension containing submicron albumin spheres is prepared, with the albumin spheres being capable of augmenting a function and effectiveness of stem cells or precursor cells in vivo. A predetermined amount of the albumin nanoparticle suspension is administered to a patient before or after an onset of at least one condition. The condition is one that can benefit from a healing effect of the stem cells or precursor cells. A function of the stem cells or precursor cells are augmented or improved by the albumin spheres to repair cellular or tissue damage, resulting in decreasing mortality or morbidity of the patient. The albumin spheres can be bound with fibrinogen molecules in vitro or in vivo.

Abstract: A method of treating radiation-induced skin toxicity or skin ulcers with nanoparticles after exposure to ionizing radiation and after an onset of radiation-induced skin toxicity or a radiation-induced skin ulcer by administering intravenously a suspension including fibrinogen-coated albumin nanospheres to a patient. A concentration of the suspension being sufficient to at least one of promote healing of the skin toxicity or reduce a size of the skin ulcer. The suspension can include fibrinogen-coated albumin nanospheres, sorbitol and/or caprylate. The suspension can be utilized for treating a patient to reduce an amount of blood loss in an organ of the patient or for treating a patient to mobilize stem cells or progenitor cells to accelerate healing of a wound.

Abstract: A product, composition, suspension and/or method to treat subjects infected with respiratory viruses, such as coronavirus, and in relieving hypoxic condition. A suspension of thrombolytic albumin nanospheres that can target vaso-occlusive clots in vivo and then lyse the obstructive blood clots with high efficiency can be intravenously administer to a subject in need thereof. The nanospheres can encapsulate an enzymatically active bioreactive agent, such as urokinase. Since the active enzyme is targeting and binding essentially only to obstructive clots, there is minimal risk of side-effects to the subject. The nanospheres are less than one micron in diameter, resulting in a size much smaller than red blood cells.

Abstract: A product and method of using albumin nanoparticles for stimulating bone heal by augmenting the function or effectiveness of stem cells or precursor cells in vivo. An albumin nanoparticle suspension containing submicron albumin spheres is prepared, with the albumin spheres being capable of augmenting a function and effectiveness of stem cells or precursor cells in vivo for healing bone fractures. A predetermined amount of the albumin nanoparticle suspension is administered to a patient after an onset of a bone fracture or bone injury. A function of the stem cells or precursor cells are augmented or improved by the albumin spheres to repair cellular or tissue damage associated with a fracture bone, resulting in decreasing mortality or morbidity of the patient. The albumin spheres can be bound with fibrinogen molecules in vitro or in vivo.

Abstract: The present invention relates to a product, method of making and method of using an albumin sphere suspension for controlling bleeding of a non-thrombocytopenic patient before, during and after surgery. An albumin sphere suspension containing submicron albumin spheres is prepared, with the albumin spheres being capable of controlling bleeding in vivo. The suspension is prepared by mixing at near freezing temperatures an albumin solution, a sub-stabilizing concentration of glutaraldehyde solution and an alcohol solution containing a stabilizing concentration of glutaraldehyde. The mixed suspension is warmed, and glycine and sorbitol being added. Lyophilization of the suspension can be performed for stabilization of the suspension.

Abstract: A method of treating radiation-induced skin toxicity or skin ulcers with nanoparticles after exposure to ionizing radiation and after an onset of radiation-induced skin toxicity or a radiation-induced skin ulcer by administering intravenously a suspension including fibrinogen-coated albumin nanospheres to a patient. A concentration of the suspension being sufficient to at least one of promote healing of the skin toxicity or reduce a size of the skin ulcer. The suspension can include fibrinogen-coated albumin nanospheres, sorbitol and/or caprylate. The suspension can be utilized for treating a patient to reduce an amount of blood loss in an organ of the patient or for treating a patient to mobilize stem cells or progenitor cells to accelerate healing of a wound.

Abstract: The present technology essentially is a portable fire damage reducing system and method including a fluid system for storing or dispensing a fluid. The fluid system can include a head unit, a body unit and a tail unit. The head unit can include a first end connectable to a fluid source. The body unit can include a first end connectable to a second end of the head unit, and a second end. The body unit can be configured to store fluid or to deliver fluid. The tail unit can include a first end connectable to the second end of the body unit, and a second end having a configuration capable of being open to the atmosphere for dispensing the fluid from the body unit or connected to the first end of the head unit to form a closed looped system with the fluid stored in the body unit.

Abstract: The present invention relates to a product, method of making and method of using an albumin sphere suspension for controlling bleeding of a non-thrombocytopenic patient before, during and after surgery. An albumin sphere suspension containing submicron albumin spheres is prepared, with the albumin spheres being capable of controlling bleeding in vivo. The suspension is prepared by mixing at near freezing temperatures an albumin solution, a sub-stabilizing concentration of glutaraldehyde solution and an alcohol solution containing a stabilizing concentration of glutaraldehyde. The mixed suspension is warmed, and glycine and sorbitol being added. Lyophilization of the suspension can be performed for stabilization of the suspension.

Abstract: The present invention relates to a product and method of using albumin nanoparticles for augmenting the function or effectiveness of stem cells or precursor cells in vivo. An albumin nanoparticle suspension containing submicron albumin spheres is prepared, with the albumin spheres being capable of augmenting a function and effectiveness of stem cells or precursor cells in vivo. A predetermined amount of the albumin nanoparticle suspension is administered to a patient before or after an onset of at least one condition. The condition is one that can benefit from a healing effect of the stem cells or precursor cells. A function of the stem cells or precursor cells are augmented or improved by the albumin spheres to repair cellular or tissue damage, resulting in decreasing mortality or morbidity of the patient. The albumin spheres can be bound with fibrinogen molecules in vitro or in vivo.

Abstract: The present invention is associated with a method of evaluating platelet function in vivo using skin-irradiation and nanoparticle radiation treatment. The present invention in the recovery of radiation skin injury suggests that radiation skin injury can be used as a substitute model to evaluate platelet substitute products instead of measuring bleeding times. Submicron nanoparticles and a future platelet treatment product are administered intravenously before and after irradiation to subjects. The resultant radiation skin injury are compared and used to evaluate the effectiveness of the platelet treatment product on platelet function in vivo. The radiation skin injury can serve as a model to evaluate platelet and platelet-substitute products, by replacing bleeding time measurements.

Abstract: The present invention relates to a product and method of using albumin nanoparticles for augmenting the function or effectiveness of stem cells or precursor cells in vivo. An albumin nanoparticle suspension containing submicron albumin spheres is prepared, with the albumin spheres being capable of augmenting a function and effectiveness of stem cells or precursor cells in vivo. A predetermined amount of the albumin nanoparticle suspension is administered to a patient before or after an onset of at least one condition. The condition is one that can benefit from a healing effect of the stem cells or precursor cells. A function of the stem cells or precursor cells are augmented or improved by the albumin spheres to repair cellular or tissue damage, resulting in decreasing mortality or morbidity of the patient. The albumin spheres can be bound with fibrinogen molecules in vitro or in vivo.

Abstract: A composition and a method effective in the production of the composition. The composition is a ready-to-use aqueous suspension in large and small quantities comprising human-fibrinogen-coated human-albumin spheres and the supernatant, said suspension being useful for the treatment of thrombocytopenic patients.

Abstract: A method of treating a patient who has extravasation of blood from an intravascular compartment to an extravascular compartment. An agent is administered to the patient which mitigates a harmful effect of break-down products of blood at an extravascular site, resulting in the patient having reduced morbidity and mortality. The morbidity and mortality of the patient is further reduced by concomitant administration of a suspension of submicron protein spheres having a molecular weight of ranging from 780 billion Daltons to less than 0.8 billion Daltons.

Abstract: A submicron protein sphere and method to intravenously treat a patient requiring blood component transfusion. The submicron protein spheres have a size ranging from 1.0 micron to less than 0.1 micron and a molecular weight ranging from 780 billion Daltons to less than 0.8 billion Daltons. The protein spheres have no biologically active molecules added or bound to the protein spheres prior to administering to the patient. The protein used to construct the spheres can be human serum albumin from natural sources or recombinant DNA-derived serum albumin, or other proteins such as gelatin or synthetic polypeptides. However, the protein spheres can bind the various clotting factors including fibrinogen after the spheres have entered the blood stream, binding the necessary additional biologically active molecules supplied in vivo from the patient's own blood, and possibly in vitro.

Abstract: A method of treating a patient exposed to radiation before the patient is thrombocytopenic, comprising: intravenous infusion of protein spheres at a concentration of the protein spheres sufficient to reduce the morbidity and mortality of the irradiated patient. The protein spheres are formed from soluble proteins without the addition of surfactants or detergents, and the protein spheres spontaneously and directly bind at least one coagulation factor without the aid of other molecules which specifically bind the at least one coagulation factor.

Abstract: The present invention relates to a method using fibrinogen-coated albumin spheres for treating a patient infected with a hemorrhagic virus. A suspension of protein nanoparticle containing submicron protein spheres is prepared and administered to the patient. The protein spheres are bound with fibrinogen molecules in vitro or in vivo. The fibrinogen-coated albumin spheres provide improved hemostatic function of a residual concentration of platelets of the patient resulting in decreasing mortality rate or decreasing morbidity of the patient. The fibrinogen-coated albumin spheres protect an endothelial function of an endothelial cell of a blood vessel of the patient resulting in improved permeability control across predetermined tissues in the patient, thereby counteracting an effect of the hemorrhagic virus on a wall of the blood vessel.

Abstract: A method of treating a patient exposed to radiation before the patient is thrombocytopenic, comprising: intravenous infusion of protein spheres at a concentration of the protein spheres sufficient to reduce the morbidity and mortality of the irradiated patient, wherein the protein spheres are formed from soluble proteins without the addition of surfactants or detergents, and the protein spheres spontaneously and directly bind at least one coagulation factor without the aid of other molecules which specifically bind the at least one coagulation factor.

Abstract: A microscopic protein device and the method of manufacture and the use of such a device for hemostasis. The device, made with biologic material such as serum albumin from a human or animal source, is less than five micron in any one dimension and typically less than one micron in diameter. It does not have any other biological or drug molecules attached to it in vitro. However, the device has properties that allow it to capture, concentrate, carry or bind biomodifying molecules, such as coagulation factor(s), or potentially other drugs, after exposure to plasma in vitro; and possibly in vivo as well. After infusion of said device intravenously inside the body, hemostatic effects can be demonstrated.